VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZBH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZBHZimmer Biomet Holdings, Inc.
$103.32$20.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZBHCash Flow

Zimmer Biomet Holdings, Inc. (ZBH) Cash Flow Statement

27Y historyFree accessUpdated daily

Free cash flow margin ranged from 11.5% to 29.8% with the latest reading at 18.1%, driven heavily by working capital timing that swung from a $173.3 million outflow to a $158.6 million inflow within two quarters, while acquisition outflows of $359.4 million in Q3 2026 indicate free cash flow is being largely deployed into M&A rather than retained.

Income StatementBalance SheetCash FlowRatios

ZBH Cash Flow Statement

Annual statement

ZBH Cash Flow Statement

Zimmer Biomet Holdings, Inc. (ZBH) cash flow statement — 27-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Cash from Operations1.88B1.7B1.5B1.58B1.28B1.5B1.2B1.59B1.75B1.58B1.63B849.8M1.06B963.1M1.15B1.18B1.19B1.12B1.04B1.08B1.04B878.2M862.2M494.8M220.2M171.8M232.4M180M
Operating CF Margin %-20.62%19.53%21.39%18.51%21.96%19.66%19.87%22.03%20.28%21.28%14.17%22.69%20.83%25.76%26.44%28.28%27.29%25.19%27.82%29.77%26.72%28.92%26.03%16.04%14.58%22.33%19.17%
Operating CF Growth %48.23%13.19%-5.2%23.11%-14.31%24.47%-24.04%-9.25%10.43%-3.06%92.07%-19.87%10.11%-16.39%-2.12%-1.39%6.8%7.65%-4.27%4.2%18.5%1.86%74.25%124.7%28.17%-26.08%29.11%-
Net Income767.5M705.1M905.2M1.03B291.2M445.5M-9.2M1.13B-379.3M1.81B304.6M146.2M719.2M778.6M752.9M760M596.9M717.4M848.6M773.2M834.5M732.5M541.8M346.3M257.8M149.8M176M150M
Depreciation & Amortization1.11B1.09B996.3M951.7M926.4M937.7M898.4M1.01B1.04B1.06B1.04B712.4M375.8M358.5M363.1M359.9M340.2M337.4M275.1M230M197.4M185.7M181.3M103.3M25.3M23.4M23.1M22M
Stock-Based Compensation97.1M90.2M101M99.8M105M76M73.8M84.3M65.5M53.7M57.3M46.4M49.4M48.5M55M60.5M62M75.3M69.9M000000000
Deferred Taxes-87.2M-87.2M-47.7M-96.3M-64.4M-102.1M39.4M-538.7M13.4M-1.78B-153.2M-164M-90.5M-126.2M-64.8M-19.7M-72.5M-19.7M2M63.9M0000007.8M0
Other Non-Cash Items-1.5M100K0-2.5M337.9M276.3M631.9M70.1M979.7M364.3M407.7M399.4M-5.7M37.8M109.1M19.3M208.3M56.5M12.7M84.4M79.6M39.3M59.4M-35.2M29.9M1.1M5.3M-9.5M
Working Capital Changes-900K-104.9M-455.4M-396.2M-311.4M-134.2M-429.8M-167.5M27.6M64.2M-23.5M-290.6M12.3M-134.1M-63.4M-3.1M58.6M-49.4M-170.2M-67.1M-70.8M-79.3M79.7M80.4M-92.8M-2.5M20.2M17.5M
Change in Receivables-160.6M-127.3M-89.7M-51.9M-184.7M-40.8M-66.2M-93.8M213.6M161.7M-141.6M-56.1M-40.4M-74.3M-45.5M-63.2M-33M-4.6M-44.4M-12.5M-76.9M-35.3M-10.6M-39M-25M2.6M7.8M0
Change in Inventory53.1M98.2M49.9M-240.4M-75.6M-8.4M-34.5M-125.2M-199.5M-120.1M77.9M-205.4M-164.6M-148.1M-67.5M7.2M25.8M36.2M-148.1M-58M-39.2M-79.2M-44.7M-53M-59.7M-50.2M-2.1M0
Change in Payables234.5M101.8M-322M-55.3M103M86.5M-95.1M-42M155.9M-133.3M32.6M-252M116.1M33.6M47.8M20M-800K00000000000
Cash from Investing-1.22B-1.98B-888.1M-778.9M-529.2M-503.6M-613.8M-729.3M-416.6M-510.8M-1.69B-7.56B-469.4M-282.5M-592.1M-624.4M-726.9M-381.2M-924.2M-491.5M-287M-311.1M-388.3M-1.1B-35.7M-54.7M-29M-33M
Capital Expenditures-136.7M-224.5M-203.8M-291.1M-187.9M-143.6M-111.9M-207.1M-162.7M-156M-184.7M-167.7M-144.9M-100M-114.7M-113.8M-79.2M-228.8M-487.9M-331.2M-268.3M-105.3M-100.8M-158.5M-33.7M-54.7M-29M-33M
CapEx % of Revenue1.6%2.73%2.65%3.94%2.71%2.1%1.83%2.59%2.05%2%2.41%2.8%3.1%2.16%2.56%2.56%1.88%5.59%11.84%8.5%7.68%3.2%3.38%8.34%2.46%4.64%2.79%3.51%
Acquisitions-526.3M-1.39B-276.3M-134.9M-99.8M0-227.1M-37.1M-15.3M-4M-1.44B-7.76B-54.3M-74.2M-59M-56.8M-82.6M-39.5M-381.8M-160.3M-28.1M-44.1M-171.3M-927.7M0000
Investments----------------------------
Other Investing-93.9M-57.5M-189.8M-74.6M-72.6M-88.3M-69.3M-217.3M-31.5M-13.8M-3M48.2M-4.1M-13.5M-17.9M-31.1M-26.8M-35.8M-109.4M09.4M-11.7M-116.2M-16.5M-2M000
Cash from Financing-1.56B326M-484.5M-763.5M-843.8M-1.31B-421.8M-779.9M-1.3B-1.21B-743.2M7.14B-562.4M-467.3M-436.5M-455.8M-489.6M-262.1M-343.5M-399.5M-730.7M-484.6M-402M664.8M-188.9M-99.1M-203.4M-147M
Debt Issued (Net)-480M1.03B536.3M54.6M-1.06B-1.05B-252.9M-716.1M-1.15B-1.25B-259.6M7.37B-247.7M-97.5M97.2M549.8M-2.2M660.3M330M018.8M-555.3M-461.4M620.6M-212.8M366.3M00
Equity Issued (Net)-801.8M-447.3M-868M-692.2M-126.4M122.5M0000-415.5M-150M-400.9M-720.8M-485.6M-1.05B-505.6M-914.2M-680M-426.5M-757.5M72.6M65M70.5M23.9M1.4M00
Dividends Paid-186.7M-190.3M-196M-200.9M-201.2M-200.1M-198.5M-196.7M-195.2M-193.6M-188.4M-157.1M-145.5M-132.4M-94.4M-510.4M000000000-290M00
Share Repurchases-829.3M-487M-868M-692.2M-126.4M00000-415.5M-150M-400.9M-720.8M-485.6M-1.05B-505.6M-923.7M-737M-576.3M-798.8M-4.1M000000
Other Financing-96.1M-65.5M43.2M75M544.5M-173.4M29.6M132.9M47.4M231.3M120.3M47.5M224M483.4M46.3M44.4M18.2M-8.2M6.5M27M8M-1.9M-5.6M-26.3M0-176.8M-203.4M-147M
Net Change in Cash-892.8M66.4M109.7M40.1M-102.8M-323.6M184.2M75.1M18.4M-109.7M-825.2M369.3M2.7M196.3M116M99.4M-22.8M479.1M-251.3M198.2M32.5M78.6M77.1M61.8M-2.7M18.4M00
Free Cash Flow1.66B1.47B1.14B1.19B1.07B1.35B1.09B1.18B1.58B1.43B1.45B682.1M915.6M863.1M1.04B1.06B1.11B852.9M440.8M753.2M772.4M772.9M761.4M336.3M186.5M117.1M203.4M147M
FCF Margin %19.33%17.89%14.88%16.05%15.38%19.73%17.83%14.8%19.98%18.28%18.88%11.37%19.59%18.67%23.19%23.88%26.2%20.83%10.7%19.33%22.1%23.52%25.54%17.69%13.59%9.94%19.55%15.65%
FCF Growth %3.47%28.88%-3.75%11.25%-20.79%23.3%-7.49%-25.47%11.11%-1.46%112.21%-25.5%6.08%-16.79%-2.44%-3.86%29.65%93.49%-41.48%-2.49%-0.06%1.51%126.4%80.32%59.27%-42.43%38.37%-
FCF per Share8.667.415.605.665.076.225.125.557.566.806.943.595.335.025.895.635.503.951.933.173.153.093.071.590.950.601.050.76
FCF Conversion (FCF/Net Income)2.16x2.41x1.66x1.54x5.55x3.73x-8.67x1.40x-4.61x0.87x5.34x5.78x1.47x1.27x1.53x1.55x2.00x1.56x1.22x1.40x1.25x1.20x1.59x1.43x0.85x1.15x1.32x1.20x
Interest Paid0000000000000000000000000000
Taxes Paid0000000000000000000000000000

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile working capital and conversion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Far Exceeds Reported Earnings

According to reported quarterly figures, ZBH's operating cash flow has run at roughly 1.5 to 3.7 times net income over the last ten quarters, a gap that suggests earnings are conservatively measured relative to cash generation, though the ratio is sensitive to working capital swings.

The consistently elevated ratio of operating cash flow to net income, with the most recent quarters at 2.92 and 2.26, suggests substantial non-cash charges such as the roughly $270 to $280 million of quarterly depreciation and amortization are depressing reported earnings. The magnitude of the gap warrants caution, however, because the ratio swings sharply with working capital movements, as the 3.71 reading in Q4 2025 was driven in part by a $158.6 million working capital inflow. Investors should monitor whether conversion holds once working capital normalizes.

Free Cash Flow Margins Remain Volatile

Based on reported figures, ZBH's free cash flow margin ranged from 11.5% to 29.8% across the last ten quarters, with the latest reading of 18.1% indicating that cash generation has not yet settled into a stable trajectory.

The wide swing in free cash flow margin, from a low of 11.5% in Q2 2024 to a peak near 30% in Q4 2025, appears to reflect timing of working capital and capital expenditures rather than a clear structural trend. The decline from the Q4 2025 peak to 18.1% in the latest quarter may suggest that the prior period benefited from one-time working capital release. Stakeholders should treat the current run rate as uncertain until multiple quarters confirm a stable level.

Working Capital Drives Quarterly Cash Variability

As reported in the quarterly statements, ZBH's working capital changes swung from a $173.3 million outflow to a $158.6 million inflow within two quarters, indicating that collections, inventory, and payables timing is a dominant driver of reported cash flow.

The large swings in working capital, including the $173.3 million outflow in Q1 2026 and the $158.6 million inflow in Q4 2025, suggest that cash conversion is highly sensitive to the timing of receivables collection and inventory build. Given the company's heavy field inventory of implant sets, these swings may partly reflect consignment and placement dynamics. The data does not allow a definitive attribution, so the sources of these movements warrant further investigation.

Capital Spending Modest Relative to Revenue

Based on reported figures, ZBH's capital expenditures have generally run between 1.7% and 9.1% of revenue, with the most recent quarter at 9.1% representing a notable step-up from the low-single-digit intensity seen through most of the period.

Capital intensity has been low for most quarters, consistent with the company's reliance on existing manufacturing infrastructure, but the 9.1% level in Q3 2026 may indicate investment in robotic platforms or manufacturing capacity. Because depreciation of roughly $280 million per quarter far exceeds most capex readings, the company appears to be underinvesting relative to asset consumption in those periods, which may warrant monitoring. Whether the recent step-up reflects growth or maintenance spending cannot be determined from the provided data.

Acquisitions Absorb Excess Free Cash Flow

According to reported cash flow statements, ZBH's acquisition outflows totaled over $1.2 billion across several recent quarters, including $359.4 million in Q3 2026, suggesting that much of the free cash flow generated has been redeployed into M&A rather than retained or returned.

Dividends have been steady at roughly $46 to $49 million per quarter, a modest share of free cash flow, while buybacks have been intermittent and in some quarters large relative to the dividend. The heavy acquisition spending, including the $1.2 billion outflow in Q3 2025, suggests management is prioritizing inorganic growth over balance sheet accumulation. Investors should assess whether these acquisitions are generating returns that justify the capital committed, as the reported figures alone do not reveal their performance.

Cash Strength May Mask Structural Constraints

Based on reported figures, the strong operating cash flow ratios could overstate durable cash generation, since quarterly free cash flow has depended heavily on working capital timing and the 2026 quarters show a sharp drop from the Q4 2025 peak.

The bull case rests on operating cash flow running well above net income, yet several of the strongest quarters coincide with large working capital inflows that may not repeat, and depreciation of roughly $280 million per quarter is a recurring cost that limits how much of the gap represents true excess cash. Stated free cash flow also excludes acquisition outflows that have absorbed substantial capital, meaning that shareholder-available cash may be lower than headline figures suggest. These observations are inferences from the supplied quarterly data and do not establish a deterioration in underlying cash generation.

ZBH — Frequently Asked Questions

Quick answers to the most common questions about buying ZBH stock.

How much cash does Zimmer Biomet Holdings, Inc. (ZBH) generate from operations?

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.70B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Zimmer Biomet Holdings, Inc.'s free cash flow?

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.47B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Zimmer Biomet Holdings, Inc.'s capital expenditure (CapEx)?

Zimmer Biomet Holdings, Inc. (ZBH) spent $224.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Zimmer Biomet Holdings, Inc. distribute cash to shareholders?

In 2025, Zimmer Biomet Holdings, Inc. (ZBH) returned $190.3M to shareholders via cash dividends and spent $487.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.